Protara Therapeutics (TARA) Stock Price, News & Analysis

Company Overview

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells. By engaging OX40, PTX-35 aims to amplify anti-tumor T-cell responses and promote durable immunity against viral antigens. The company has also advanced preclinical vaccine programs targeting high-grade cervical dysplasia driven by HPV-16 and HPV-18, with the goal of reducing the need for surgical intervention.

Headquartered in San Diego, California, Protara conducts early-stage clinical trials in North America and collaborates with academic research centers to explore combination regimens and next-generation immuno-oncology approaches. As a Nasdaq-listed company under the ticker TARA, Protara Therapeutics continues to build its pipeline through internal research and strategic partnerships aimed at addressing unmet needs in virus-associated oncology.

Key Stats

• Today's Range: $5.36 to $5.64
• 50-Day Range: $4.85 to $7.43
• 52-Week Range: $2.77 to $7.82
• Volume: 471,390 shs
• Average Volume: 981,597 shs
• Market Capitalization: $297.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.75
• Consensus Rating: Moderate Buy

Protara Therapeutics Stock Analysis - MarketRank™

Protara Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 499th out of 854 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Protara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Protara Therapeutics has a consensus price target of $24.75, representing about 359.6% upside from its current price of $5.39.

Amount of Analyst Coverage

Protara Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.58) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protara Therapeutics is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protara Therapeutics is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protara Therapeutics has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.39% of the float of Protara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 11.15, which indicates bearish sentiment.

Change versus previous month

Short interest in Protara Therapeutics has recently increased by 3.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protara Therapeutics does not currently pay a dividend.

Dividend Growth

Protara Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.67

News Sentiment

Protara Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for TARA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

4 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Protara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $124,989.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Protara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

38.13% of the stock of Protara Therapeutics is held by institutions.

TARA Stock Analysis - Frequently Asked Questions

How have TARA shares performed this year?

Protara Therapeutics' stock was trading at $5.33 at the start of the year. Since then, TARA shares have increased by 1.0% and is now trading at $5.3850.

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) released its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03.

When did Protara Therapeutics IPO?

Protara Therapeutics (TARA) raised $79 million in an initial public offering (IPO) on Wednesday, October 22nd 2014. The company issued 6,110,000 shares at a price of $12.00-$14.00 per share.

Who are Protara Therapeutics' major shareholders?

Top institutional investors of Protara Therapeutics include AIGH Capital Management LLC (2.95%) and Assenagon Asset Management S.A. (1.05%). Insiders that own company stock include Jacqueline Zummo and Opaleye Management Inc.
View institutional ownership trends.

How do I buy shares of Protara Therapeutics?

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/10/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TARA
• Previous Symbol: NASDAQ:PRTO
• CIK: 1359931
• Web: www.proteontherapeutics.com
• Phone: (646) 844-0337
• Fax: 781-487-6729
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Protara Therapeutics: $24.75
• High Price Target: $27.00
• Low Price Target: $21.00
• Potential Upside/Downside: +357.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -36.38%
• Return on Assets: -33.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.58
• Quick Ratio: 14.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.80 per share
• Price / Book: 1.42

Miscellaneous

• Outstanding Shares: 55,061,000
• Free Float: 48,178,000
• Market Cap: $297.88 million
• Optionable: Optionable
• Beta: 1.53